← Human Trials & Peer-Reviewed Studies
A Study of a Weight Loss Intervention in People With Endometrial Cancer
Plain-language guide to NCT06751589: early phase 1 interventional trial of Tirzepatide, endometriosis, 36 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT06751589
- Phase
- early phase 1
- Status
- recruiting participants
- Start
- 2024-12-19
- Completion (planned or actual)
- 2027-12
- Participants
- 36 (estimated)
- Design
- na, open label (everyone knows who gets what), treatment
- Conditions studied
- Endometrial Cancer
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
This registered early phase 1 trial tested Tirzepatide for endometriosis.
The researchers will also look at participants' experience with the study drug, the safety of taking the study drug while receiving chemotherapy, and changes in weight, body fat composition, and blood pressure of participants.
It had 1 arm (groups): tirzepatide (experimental).
The registry classes the interventions as drug.
Who Took Part
The registry lists 36 planned participants were the target.
It was open to women only aged from 18 years with no upper age limit.
Healthy volunteers were not accepted; participants needed the condition being studied.
Examples of who could join: Age ≥ 18 years. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2. Completed surgery with TH/BSO with no gross residual disease. Patient has adequate organ function, as defined by the following laboratory values:. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0 × ULN.
The full record lists 16 inclusion and 12 exclusion criteria; among the exclusions: known type 1 diabetes; known gad, islet cell, or zn transporter 8 antibodies; history of gastroparesis.
How the Study Was Run
The set-up was single-group and open-label.
Being open-label, the Tirzepatide study did not mask who received what.
Everyone received the same intervention, so there was no separate comparison group inside the trial.
It started in 2024-12-19 with completion listed for 2027-12.
It ran at 7 sites in United States (7).
Its stated primary purpose is treatment.
What Was Measured
Primary outcome: percentage of patients that complete treatment (time frame: 1 year).
It also tracked 1 secondary outcome, for example frequency of gastrointestinal adverse events.
What This Means in Plain Language
Put simply, this is a early phase 1 trial of Tirzepatide in 36 people with endometriosis.
Its size is small, so on its own it can only give an early look.
It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the Tirzepatide compound page, Endometriosis research.
Our Notes on the Compound
Tirzepatide: A prescription peptide medicine that acts on both the GIP and GLP-1 receptors; Mounjaro and Zepbound contain the same active ingredient.
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.